Federal government spending for Medicare Part D catastrophic coverage soared in recent years, largely thanks to fast-rising prices for expensive specialty drugs used to combat hepatitis C, cancer, and multiple sclerosis, according to a new report from the Department of Health and Human Services.
Specifically, the Part D plan paid $33.2 billion in 2015, up 208 percent from $10.8 billion in 2010, for pricey specialty medicines that are needed by beneficiaries once they left the so-called donut hole. This term refers to the moment when their annual out-of-pocket costs exceed a certain threshold, which was $4,700 in 2015. At that point, prescription drug coverage is called catastrophic coverage.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
This is outrageous. Amazing how crooked the pharmaceutical companies are and get away with it. Something has to be done.